Press

Study identifies a targetable lung cancer mutation - 29thOctober2018

Scientists from MedGenome, Bangalore, India in collaboration with oncologists from Tata Memorial Hospital, Mumbai, India and scientists at Genentech, a member of the Roche Group, South San Francisco, Calif., USA, report in Cancer Cell the identification of a treatable mutation linked to lung cancer. A mutation in HER2, a gene normally amplified in breast cancer, was found mutated in a familial lung cancer patient. Based on the mutation profile the patient was treated with an approved HER2 inhibitor that normally is used for treating breast cancer. The study also reports several additional actionable activating HER2 mutations in multiple cancers in the same region of HER2 as observed in the lung cancer patient.

MedGenome’s study suggests a personalized cancer vaccine approach to treat Lynch Syndrome - 21stAugust2018

The published study examines the feasibility of treating Lynch syndrome using a personalized cancer vaccine approach by identifying potential immunogenic tumor specific alterations.

Lynch syndrome is a hereditary cancer arising from loss of function mutations in DNA mismatch repair genes, such as MLH1, MSH2, MSH3, MSH6, PMS2, and EPCAM. “Over 1 million Americans are affected by Lynch syndrome according to the Cancer Moonshot Blue Ribbon Panel, wherein only 5% are aware of this” said Prof Henry T. Lynch whose groundbreaking research in 1960s led to the discovery of cancer family syndrome or hereditary nonpolyposis colorectal cancer (HNPCC) also referred to as Lynch syndrome.

MedGenome’s OncoPept™ Named ‘Best Overall Genomics Solution’ in 2018 MedTech Breakthrough Awards - 06thJune2018

MedGenome’s OncoPept™ platform of advanced genomics-based solutions designed to accelerate cancer immune-oncology research, was named the winner of the 2018 MedTech Breakthrough Awards for ‘Best Overall Genomics Solution.’

MedGenome raises additional $10 mn in Series C from HDFC - 05thMarch2018

Leading genetics diagnostics firm MedGenome Labs Ltd said it has completed its Series C round of $40 million after getting an additional $10 million from private lender HDFC Ltd, insurer HDFC Life and HDFC Asset Management.

Last August, it had raised $30 million in Series C from Sequoia India and Sofina s.a., with participation by Zodius Capital; Kris Gopalakrishnan, co-founder and former CEO of Infosys; and Lakshmi Narayanan, former CEO of Cognizant.

Considering Genomic Research?
*
 
*
*
 


2019 © MedGenome • All Rights Reserved